Cargando…

Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis

BACKGROUND: The Chinese government implemented the first round of National Centralized Drug Procurement (NCDP) pilot (so-called “4 + 7” policy) in mainland China in 2019. This study aims to examine the impact of “4 + 7” policy on the price of policy-related drugs. METHODS: This study used drug purch...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ni, Yang, Ying, Xu, Luxinyi, Mao, Zongfu, Cui, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524972/
https://www.ncbi.nlm.nih.gov/pubmed/34663282
http://dx.doi.org/10.1186/s12889-021-11882-7
_version_ 1784585581960888320
author Wang, Ni
Yang, Ying
Xu, Luxinyi
Mao, Zongfu
Cui, Dan
author_facet Wang, Ni
Yang, Ying
Xu, Luxinyi
Mao, Zongfu
Cui, Dan
author_sort Wang, Ni
collection PubMed
description BACKGROUND: The Chinese government implemented the first round of National Centralized Drug Procurement (NCDP) pilot (so-called “4 + 7” policy) in mainland China in 2019. This study aims to examine the impact of “4 + 7” policy on the price of policy-related drugs. METHODS: This study used drug purchasing order data from the Centralized Drug Procurement Survey in Shenzhen 2019, covering 24 months from January 2018 to December 2019. “4 + 7” policy-related drugs were selected as study samples, including 25 drugs in the “4 + 7” procurement list and 57 alternative drugs that have an alternative relationship with “4 + 7” List drugs in clinical use. “4 + 7” List drugs were then divided into bid-winning and bid-non-winning products according to the bidding results. Single-group Interruption Time Series (ITS) analysis was adopted to examine the change of Drug Price Index (DPI) for policy-related drugs. RESULTS: The ITS analysis showed that the DPI of winning (− 0.183 per month, p < 0.0001) and non-winning (− 0.034 per month, p = 0.046) products significantly decreased after the implementation of “4 + 7” policy. No significant difference was found for the immediate change of DPI for alternative drugs (p = 0.537), while a significant decrease in change trend was detected in the post-“4 + 7” policy period (− 0.003 per month, p = 0.014). The DPI of the overall policy-related drugs significantly decreased (− 0.261 per month, p < 0.0001) after “4 + 7” policy. CONCLUSIONS: These findings indicate that the price behavior of pharmaceutical enterprises changed under NCDP policy, while the price linkage effect is still limited. It is necessary to further expand the scope of centralized purchased drugs and strengthen the monitoring of related drugs regarding price change and consumption structure. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-021-11882-7.
format Online
Article
Text
id pubmed-8524972
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85249722021-10-22 Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis Wang, Ni Yang, Ying Xu, Luxinyi Mao, Zongfu Cui, Dan BMC Public Health Research BACKGROUND: The Chinese government implemented the first round of National Centralized Drug Procurement (NCDP) pilot (so-called “4 + 7” policy) in mainland China in 2019. This study aims to examine the impact of “4 + 7” policy on the price of policy-related drugs. METHODS: This study used drug purchasing order data from the Centralized Drug Procurement Survey in Shenzhen 2019, covering 24 months from January 2018 to December 2019. “4 + 7” policy-related drugs were selected as study samples, including 25 drugs in the “4 + 7” procurement list and 57 alternative drugs that have an alternative relationship with “4 + 7” List drugs in clinical use. “4 + 7” List drugs were then divided into bid-winning and bid-non-winning products according to the bidding results. Single-group Interruption Time Series (ITS) analysis was adopted to examine the change of Drug Price Index (DPI) for policy-related drugs. RESULTS: The ITS analysis showed that the DPI of winning (− 0.183 per month, p < 0.0001) and non-winning (− 0.034 per month, p = 0.046) products significantly decreased after the implementation of “4 + 7” policy. No significant difference was found for the immediate change of DPI for alternative drugs (p = 0.537), while a significant decrease in change trend was detected in the post-“4 + 7” policy period (− 0.003 per month, p = 0.014). The DPI of the overall policy-related drugs significantly decreased (− 0.261 per month, p < 0.0001) after “4 + 7” policy. CONCLUSIONS: These findings indicate that the price behavior of pharmaceutical enterprises changed under NCDP policy, while the price linkage effect is still limited. It is necessary to further expand the scope of centralized purchased drugs and strengthen the monitoring of related drugs regarding price change and consumption structure. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-021-11882-7. BioMed Central 2021-10-19 /pmc/articles/PMC8524972/ /pubmed/34663282 http://dx.doi.org/10.1186/s12889-021-11882-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Ni
Yang, Ying
Xu, Luxinyi
Mao, Zongfu
Cui, Dan
Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis
title Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis
title_full Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis
title_fullStr Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis
title_full_unstemmed Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis
title_short Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis
title_sort influence of chinese national centralized drug procurement on the price of policy-related drugs: an interrupted time series analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524972/
https://www.ncbi.nlm.nih.gov/pubmed/34663282
http://dx.doi.org/10.1186/s12889-021-11882-7
work_keys_str_mv AT wangni influenceofchinesenationalcentralizeddrugprocurementonthepriceofpolicyrelateddrugsaninterruptedtimeseriesanalysis
AT yangying influenceofchinesenationalcentralizeddrugprocurementonthepriceofpolicyrelateddrugsaninterruptedtimeseriesanalysis
AT xuluxinyi influenceofchinesenationalcentralizeddrugprocurementonthepriceofpolicyrelateddrugsaninterruptedtimeseriesanalysis
AT maozongfu influenceofchinesenationalcentralizeddrugprocurementonthepriceofpolicyrelateddrugsaninterruptedtimeseriesanalysis
AT cuidan influenceofchinesenationalcentralizeddrugprocurementonthepriceofpolicyrelateddrugsaninterruptedtimeseriesanalysis